Loading...
XSTO
GABA
Market cap801kUSD
Jul 09, Last price  
0.03SEK
1D
-7.34%
1Q
-13.68%
Jan 2017
-99.93%
IPO
-99.82%
Name

Gabather AB

Chart & Performance

D1W1MN
XSTO:GABA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
70.35%
Rev. gr., 5y
-52.95%
Revenues
0k
Net income
-5m
L-40.00%
-2,586,000-5,964,800-7,894,150-9,938,000-20,314,000-14,281,571-14,949,000-16,999,000-8,545,000-9,437,000-7,753,000-4,652,000
CFO
-7m
L+117.07%
0-5,472,657-7,085,793-9,675,835-20,051,705-13,682,877-13,692,000-16,117,000-9,597,000-11,643,000-3,328,000-7,224,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.
URL
https://www.gabather.com/
IPO date
Nov 03, 2014
Employees
3
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT